These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 35696861)

  • 1. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
    Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
    Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
    Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
    Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
    Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
    J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase.
    Liu J; Ren J; Yang K; Chen S; Yang X; Zhao QS
    Eur J Med Chem; 2022 May; 235():114294. PubMed ID: 35358772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
    Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
    Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
    Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
    Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
    Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
    Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
    Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
    Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
    Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
    Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies.
    Jiang K; Wang Q; Chen XL; Wang X; Gu X; Feng S; Wu J; Shang H; Ba X; Zhang Y; Tang K
    Int J Nanomedicine; 2024; 19():8847-8882. PubMed ID: 39220190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
    Front Immunol; 2022; 13():807271. PubMed ID: 35173722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
    Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
    Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
    Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
    Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
    Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
    Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase.
    Yoshioka S; Ikeda T; Fukuchi S; Kawai Y; Ohta K; Murakami H; Ogo N; Muraoka D; Takikawa O; Asai A
    Int J Tryptophan Res; 2022; 15():11786469221138456. PubMed ID: 36467776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
    Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
    Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW; Bao R; Luke JJ
    Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.